TipRanks
Viking Therapeutics (GB:0VQA)
LSE:0VQA
UK Market
0VQA
Viking Therapeutics
RESEARCH TOOLSreports

Viking Therapeutics (0VQA) Share Forecast & Price Target

13 Followers
See the Price Targets and Ratings of:

0VQA Analyst Ratings

Strong Buy
17Ratings
Strong Buy
16 Buy
1 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Viking
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0VQA Stock 12 Month Forecast

Average Price Target

$92.06
▲(182.57% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $92.06 with a high forecast of $125.00 and a low forecast of $38.00. The average price target represents a 182.57% change from the last price of $32.58.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"25":"$25","126":"$126","50.25":"$50.3","75.5":"$75.5","100.75":"$100.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":92.0625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$92.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$38.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[25,50.25,75.5,100.75,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.15,38.36923076923077,45.58846153846154,52.80769230769231,60.02692307692307,67.24615384615385,74.46538461538461,81.68461538461537,88.90384615384615,96.12307692307692,103.34230769230768,110.56153846153845,117.78076923076921,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.15,35.83557692307692,40.521153846153844,45.206730769230774,49.892307692307696,54.57788461538462,59.26346153846154,63.949038461538464,68.63461538461539,73.32019230769231,78.00576923076923,82.69134615384615,87.37692307692308,{"y":92.0625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.15,31.676923076923075,32.20384615384615,32.730769230769226,33.25769230769231,33.784615384615385,34.31153846153846,34.83846153846154,35.36538461538461,35.89230769230769,36.419230769230765,36.94615384615385,37.473076923076924,{"y":38,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":26.89,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.836,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.122,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.241,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.938,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.594,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.11,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.32,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.72,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.72,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.29,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.99,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.15,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$125.00Average Price Target$92.06Lowest Price Target$38.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on GB:0VQA
Edward Nash
Canaccord Genuity
Canaccord Genuity
$114
Buy
249.91%
Upside
Reiterated
10/07/26
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Rocket Pharmaceuticals (RCKT)
Truist Financial Analyst forecast on GB:0VQA
Gregory Renza
Truist Financial
Truist Financial
$87→$85
Buy
160.90%
Upside
Reiterated
10/07/26
Viking Therapeutics price target lowered to $85 from $87 at TruistViking Therapeutics price target lowered to $85 from $87 at Truist
H.C. Wainwright Analyst forecast on GB:0VQA
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$102
Buy
213.08%
Upside
Reiterated
10/06/26
Viking Therapeutics: VK2735 Maintenance Data Reinforces Obesity Franchise; Buy Rating and $102 Price Target Reiterated
Morgan Stanley Analyst forecast on GB:0VQA
Michael Ulz
Morgan Stanley
Morgan Stanley
$95
Buy
191.59%
Upside
Reiterated
10/06/26
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (NASDAQ: FDMT) and Viking Therapeutics (NASDAQ: VKTX)
Maxim Group Analyst forecast on GB:0VQA
Naz Rahman
Maxim Group
Maxim Group
$70
Buy
114.86%
Upside
Reiterated
10/06/26
Analyst Maintains Buy Rating on Viking Therapeutics, Keeps VK2735-Driven Price Target at $70
Leerink Partners Analyst forecast on GB:0VQA
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$118
Buy
262.19%
Upside
Reiterated
09/23/26
Leerink Partners Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
Jefferies Analyst forecast on GB:0VQA
Roger Song
Jefferies
Jefferies
$101
Buy
210.01%
Upside
Reiterated
09/23/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
B. Riley Securities Analyst forecast on GB:0VQA
William Wood
B. Riley Securities
B. Riley Securities
$85
Buy
160.90%
Upside
Reiterated
09/23/26
Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Lyell Immunopharma (LYEL)
Lake Street Analyst forecast on GB:0VQA
Daniel Brims
Lake Street
Lake Street
$89
Buy
173.17%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE), Viking Therapeutics (NASDAQ: VKTX) and Aytu BioScience (NASDAQ: AYTU)
Oppenheimer Analyst forecast on GB:0VQA
Jay Olson
Oppenheimer
Oppenheimer
$100→$120
Buy
268.32%
Upside
Assigned
09/22/26
Viking Therapeutics price target raised to $120 from $100 at OppenheimerViking Therapeutics price target raised to $120 from $100 at Oppenheimer
Stifel Nicolaus Analyst forecast on GB:0VQA
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$30→$95
Buy
191.59%
Upside
Reiterated
09/22/26
Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Palisade Bio (PALI)
BTIG Analyst forecast on GB:0VQA
Jeet Mukherjee
BTIG
BTIG
$125
Buy
283.67%
Upside
Reiterated
09/22/26
Analysts Are Bullish on Top Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Viking Therapeutics (VKTX)
William Blair Analyst forecast on GB:0VQA
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
09/22/26
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (NASDAQ: VKTX) and Relay Therapeutics (NASDAQ: RLAY)
Goldman Sachs Analyst forecast on GB:0VQA
Richard Law CFA
Goldman Sachs
Goldman Sachs
$35→$38
Hold
16.64%
Upside
Reiterated
09/22/26
Viking Therapeutics (VKTX) Gets a Hold from Goldman Sachs
Cantor Fitzgerald Analyst forecast on GB:0VQA
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$100
Buy
206.94%
Upside
Reiterated
08/14/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on GB:0VQA
Edward Nash
Canaccord Genuity
Canaccord Genuity
$114
Buy
249.91%
Upside
Reiterated
10/07/26
Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Rocket Pharmaceuticals (RCKT)
Truist Financial Analyst forecast on GB:0VQA
Gregory Renza
Truist Financial
Truist Financial
$87→$85
Buy
160.90%
Upside
Reiterated
10/07/26
Viking Therapeutics price target lowered to $85 from $87 at TruistViking Therapeutics price target lowered to $85 from $87 at Truist
H.C. Wainwright Analyst forecast on GB:0VQA
Joseph Pantginis
H.C. Wainwright
H.C. Wainwright
$102
Buy
213.08%
Upside
Reiterated
10/06/26
Viking Therapeutics: VK2735 Maintenance Data Reinforces Obesity Franchise; Buy Rating and $102 Price Target Reiterated
Morgan Stanley Analyst forecast on GB:0VQA
Michael Ulz
Morgan Stanley
Morgan Stanley
$95
Buy
191.59%
Upside
Reiterated
10/06/26
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (NASDAQ: FDMT) and Viking Therapeutics (NASDAQ: VKTX)
Maxim Group Analyst forecast on GB:0VQA
Naz Rahman
Maxim Group
Maxim Group
$70
Buy
114.86%
Upside
Reiterated
10/06/26
Analyst Maintains Buy Rating on Viking Therapeutics, Keeps VK2735-Driven Price Target at $70
Leerink Partners Analyst forecast on GB:0VQA
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$118
Buy
262.19%
Upside
Reiterated
09/23/26
Leerink Partners Sticks to Their Buy Rating for Viking Therapeutics (VKTX)
Jefferies Analyst forecast on GB:0VQA
Roger Song
Jefferies
Jefferies
$101
Buy
210.01%
Upside
Reiterated
09/23/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
B. Riley Securities Analyst forecast on GB:0VQA
William Wood
B. Riley Securities
B. Riley Securities
$85
Buy
160.90%
Upside
Reiterated
09/23/26
Analysts Are Bullish on These Healthcare Stocks: Lineage Therap (LCTX), Lyell Immunopharma (LYEL)
Lake Street Analyst forecast on GB:0VQA
Daniel Brims
Lake Street
Lake Street
$89
Buy
173.17%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE), Viking Therapeutics (NASDAQ: VKTX) and Aytu BioScience (NASDAQ: AYTU)
Oppenheimer Analyst forecast on GB:0VQA
Jay Olson
Oppenheimer
Oppenheimer
$100→$120
Buy
268.32%
Upside
Assigned
09/22/26
Viking Therapeutics price target raised to $120 from $100 at OppenheimerViking Therapeutics price target raised to $120 from $100 at Oppenheimer
Stifel Nicolaus Analyst forecast on GB:0VQA
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$30→$95
Buy
191.59%
Upside
Reiterated
09/22/26
Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Palisade Bio (PALI)
BTIG Analyst forecast on GB:0VQA
Jeet Mukherjee
BTIG
BTIG
$125
Buy
283.67%
Upside
Reiterated
09/22/26
Analysts Are Bullish on Top Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Viking Therapeutics (VKTX)
William Blair Analyst forecast on GB:0VQA
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
09/22/26
Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (NASDAQ: VKTX) and Relay Therapeutics (NASDAQ: RLAY)
Goldman Sachs Analyst forecast on GB:0VQA
Richard Law CFA
Goldman Sachs
Goldman Sachs
$35→$38
Hold
16.64%
Upside
Reiterated
09/22/26
Viking Therapeutics (VKTX) Gets a Hold from Goldman Sachs
Cantor Fitzgerald Analyst forecast on GB:0VQA
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$100
Buy
206.94%
Upside
Reiterated
08/14/26
Cantor Fitzgerald Reaffirms Their Buy Rating on Viking Therapeutics (VKTX)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
IMUXImmunic
REPLReplimune Group
OVIDOvid Therapeutics
CELCCelcuity
ARDXArdelyx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Viking Therapeutics

3 Months
Jay OlsonOppenheimer
Success Rate
13/23 ratings generated profit
57%
Average Return
+32.57%
Copying Jay Olson's trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +32.57% per trade.
1 Year
Thomas SmithLeerink Partners
Success Rate
12/21 ratings generated profit
57%
Average Return
+82.39%
Copying Thomas Smith's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +82.39% per trade.
2 Years
Thomas SmithLeerink Partners
Success Rate
11/21 ratings generated profit
52%
Average Return
+49.94%
Copying Thomas Smith's trades and holding each position for 2 Years would result in 52.38% of your transactions generating a profit, with an average return of +49.94% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0VQA Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
16
23
21
29
21
Buy
4
5
5
3
1
Hold
0
0
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
20
28
26
33
23
In the current month, 0VQA has received 22 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0VQA average Analyst price target in the past 3 months is 92.06.
Each month's total comprises the sum of three months' worth of ratings.

0VQA Financial Forecast

0VQA Earnings Forecast

Next quarter’s earnings estimate for 0VQA is -$1.07 with a range of -$1.38 to -$0.66. The previous quarter’s EPS was -$1.10. 0VQA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0VQA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0VQA is -$1.07 with a range of -$1.38 to -$0.66. The previous quarter’s EPS was -$1.10. 0VQA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0VQA has Performed in-line its overall industry.
No data currently available

0VQA Sales Forecast

Next quarter’s sales forecast for 0VQA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. 0VQA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0VQA has Performed in-line its overall industry.
Next quarter’s sales forecast for 0VQA is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. 0VQA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0VQA has Performed in-line its overall industry.

0VQA Stock Forecast FAQ

What is GB:0VQA’s average 12-month price target, according to analysts?
Based on analyst ratings, Viking Therapeutics’s 12-month average price target is 92.06.
    What is GB:0VQA’s upside potential, based on the analysts’ average price target?
    Viking Therapeutics has 182.57% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Viking Therapeutics a Buy, Sell or Hold?
          Viking Therapeutics has a consensus rating of Strong Buy, which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Viking Therapeutics’s share price target?
            The average share price target for Viking Therapeutics is 92.06. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $125.00 ,and the lowest forecast is $38.00. The average share price target represents 182.57% Increase from the current price of $32.58.
              What do analysts say about Viking Therapeutics?
              Viking Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of Viking Therapeutics?
                To buy shares of GB:0VQA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.